Education · Tier 1

· Last Reviewed May 15, 2026· PSI Editorial Board· Independent

What Are Peptides?

The honest reference for peptide therapy basics anchored in FDA prescribing information, AMA Code of Medical Ethics, FDA Compounding Quality Act of 2013, and peer-reviewed cardiovascular outcomes evidence.

Peptides are short amino acid chains that function as biological signals in the body.

The class spans FDA-approved drugs like Wegovy and Ozempic and compounded preparations like BPC-157 and thymosin alpha-1.

The regulatory frameworks differ in important ways.

10+ FDA

FDA-Approved Peptides

Wegovy, Ozempic, Zepbound, Mounjaro, Forteo, Tymlos, Evenity, Saxenda, Tesamorelin, Vyleesi covered

6 Classes

Indication Classes

Metabolic, immune, tissue repair, growth hormone, sexual health, bone health peptide classes

L1 to L4

Evidence Framework

Preclinical (L1), animal studies (L2), human trials (L3), FDA-approved (L4) evidence levels

AMA 1.1.5

Off-Label Framework

AMA Code of Medical Ethics 1.1.5 governs off-label and compounded prescribing decisions

Quick Answer

Peptides are short amino acid chains, typically fewer than 50 amino acids, that function as biological signals between cells. The class spans FDA-approved peptide drugs and compounded peptide preparations under different regulatory frameworks.

FDA-approved peptide drugs include Semaglutide (Wegovy NDA 215256, Ozempic NDA 209637) and Tirzepatide (Zepbound NDA 217806, Mounjaro NDA 215866). Additional examples include Teriparatide (Forteo NDA 021318 for osteoporosis) and Tesamorelin (Egrifta NDA 022505 for HIV-associated lipodystrophy). FDA pre-market review includes Phase 3 trial evidence.

For compounded peptide preparations, the framework operates under the FDA Compounding Quality Act of 2013. The 503A pathway covers individual prescription compounding through state pharmacy board licensed pharmacies. The 503B pathway covers office-administered preparations through FDA-registered outsourcing facilities. Neither category receives FDA pre-market approval. AMA Code of Medical Ethics 1.1.5 governs off-label and compounded prescribing.

Evidence levels for peptide therapy span four tiers. Preclinical (L1) covers in vitro and mechanistic studies. Animal studies (L2) cover rodent and large-animal work without human data. Human trials (L3) cover any human trial data including pilot and Phase 1 through Phase 3. FDA-approved (L4) covers compounds with completed FDA pre-market review.

Indication classes span metabolic peptides (GLP-1 receptor agonists), anabolic osteoporosis peptides (PTH analogs, sclerostin antibodies), and growth hormone secretagogues (sermorelin, tesamorelin). Additional classes include tissue repair peptides (BPC-157, TB-500), sexual health peptides (bremelanotide Vyleesi NDA 210557), and immune peptides (thymosin alpha-1).

Monitoring follows a four-stage cadence for any peptide therapy. The stages are baseline at week 0, early follow-up at week 4 to 8, stabilization at month 3, and maintenance at month 6. See Bloodwork Before Peptide Therapy for the foundational framework. Also see Compounded vs FDA-Approved Peptides for the regulatory pathway distinction.

Peptide drugs receive FDA pre-market approval based on Phase 3 trial evidence and label-specific indications. Compounded peptide preparations route through 503A pharmacies or 503B outsourcing facilities under the FDA Compounding Quality Act of 2013. The compounded pathway operates outside FDA pre-market approval. AMA Code of Medical Ethics 1.1.5 governs off-label and compounded prescribing. The evidence base for peptide therapy spans preclinical animal studies, human clinical trials, and FDA-approved indication-specific labels. Patients should consult primary care or specialty practice for individualized clinical context.

PEPTIDES 101 GATEWAY

At a Glance: Peptides 101

Concept	Subtitle	Animal Evidence	Human Evidence	Clinical Anchoring
Peptide definition	Short amino acid chains, typically fewer than 50 amino acids	—	Strong	Peptides function as biological signals between cells, including hormones, neurotransmitters, and immune modulators
FDA-approved peptide drugs	Wegovy, Ozempic, Zepbound, Mounjaro, Forteo, Tymlos, Evenity	—	Strong	FDA pre-market review includes Phase 3 trial evidence, indication-specific labels, and post-marketing surveillance
Compounded peptide preparations	503A pharmacy and 503B outsourcing facility framework	—	Moderate	FDA Compounding Quality Act of 2013 framework. AMA Code of Medical Ethics 1.1.5 governs off-label and compounded prescribing
Evidence-level framework (L1 to L4)	Preclinical, animal studies, human trials, FDA-approved	—	Strong	L1 in vitro and mechanistic, L2 animal studies, L3 human trial data including Phase 1 through 3, L4 FDA-approved
Indication classes	Metabolic, immune, tissue repair, growth hormone, sexual health, bone health	—	Strong	Six primary indication classes span the FDA-approved and compounded peptide therapy landscape
Physician prescription required	Both FDA-approved and compounded peptides require physician prescription	—	Strong	Self-sourcing from research chemical suppliers operates outside the validated clinical practice framework
Baseline bloodwork required	Indication-specific panel before peptide therapy initiation	—	Strong	Per FDA labels for FDA-approved peptides and AMA Code 1.1.5 for compounded peptides
Four-stage monitoring cadence	Baseline, early follow-up, stabilization, maintenance	—	Strong	Baseline week 0, early follow-up week 4-8, stabilization month 3, maintenance month 6 plus annual

Six Things You Need to Know About Peptides

This page covers peptide therapy basics in detail. Section one covers the peptide definition and biological function. Section two covers FDA-approved peptide drugs and the FDA pre-market review framework. Section three covers compounded peptide preparations under the FDA Compounding Quality Act of 2013. Section four covers the evidence-level framework spanning preclinical to FDA-approved tiers across indication classes.

Peptides Are Short Amino Acid Chains That Function as Biological Signals

Peptides are short amino acid chains, typically fewer than 50 amino acids, that function as biological signals between cells. The class spans naturally occurring hormones, neurotransmitters, immune modulators, and synthetic therapeutic agents.

Amino acids are the building blocks of proteins. A peptide is a short chain of amino acids linked by peptide bonds. The conventional boundary between peptide and protein is approximately 50 amino acids. Peptides function as biological signals throughout the body. Endogenous peptide hormones include insulin (regulates glucose metabolism), glucagon (counterregulates glucose), growth hormone-releasing hormone (GHRH stimulates pituitary growth hormone release), and many others. Neuropeptides include enkephalins and endorphins (endogenous opioid signaling), oxytocin (social bonding and labor contraction), and vasopressin (water balance). Immune peptides include alpha-defensins (antimicrobial), thymosins (T cell maturation), and many cytokine signaling peptides. Therapeutic peptides are designed or derived from endogenous templates to achieve specific receptor-mediated effects with controlled pharmacokinetics. Synthetic modifications including pegylation, fatty acid conjugation, and amino acid substitution extend half-life and improve receptor selectivity. The peptide drug class has grown substantially since the early 1980s when recombinant human insulin became the first major FDA-approved peptide therapeutic.

FDA-Approved Peptide Drugs Receive Pre-Market Review Including Phase 3 Trial Evidence

FDA-approved peptide drugs have undergone FDA pre-market review including Phase 3 trial evidence supporting safety and efficacy for the specific indication on the FDA label. Examples include Wegovy, Ozempic, Zepbound, Mounjaro, Forteo, Tymlos, and Evenity.

FDA pre-market review for peptide drugs follows the New Drug Application (NDA) process. The process includes preclinical safety pharmacology, Phase 1 first-in-human safety and pharmacokinetics, Phase 2 dose-finding and proof-of-concept, and Phase 3 pivotal efficacy and safety trials at therapeutic dose. Examples of FDA-approved peptide drugs include Wegovy (semaglutide NDA 215256 for chronic weight management) anchored in STEP and SELECT cardiovascular outcomes trials. Ozempic (semaglutide NDA 209637 for type 2 diabetes) anchored in SUSTAIN trial program. Zepbound (tirzepatide NDA 217806 for chronic weight management) anchored in SURMOUNT-1 trial. Mounjaro (tirzepatide NDA 215866 for type 2 diabetes) anchored in SURPASS trial program. Forteo (teriparatide NDA 021318 for high fracture risk osteoporosis) anchored in VERT trial. Tymlos (abaloparatide NDA 208743 for postmenopausal osteoporosis) anchored in ACTIVE trial. Evenity (romosozumab NDA 761062 for postmenopausal osteoporosis with cardiovascular boxed warning) anchored in FRAME and ARCH trials. Saxenda (liraglutide for chronic weight management) anchored in SCALE trials. Tesamorelin (Egrifta NDA 022505 for HIV-associated lipodystrophy) anchored in LIPO trials. Vyleesi (bremelanotide NDA 210557 for hypoactive sexual desire disorder in premenopausal women) anchored in RECONNECT trials. The FDA-approved framework provides the strongest evidence anchoring across the peptide drug class.

Compounded Peptide Preparations Operate Under the FDA Compounding Quality Act of 2013

Compounded peptide preparations route through 503A pharmacies or 503B outsourcing facilities under the FDA Compounding Quality Act of 2013. Neither category receives FDA pre-market approval. AMA Code of Medical Ethics 1.1.5 governs off-label and compounded prescribing.

The FDA Compounding Quality Act of 2013 (Drug Quality and Security Act framework) established two compounding categories. The 503A pathway covers individual prescription compounding through state pharmacy board licensed compounding pharmacies. State license verification is through the state pharmacy board portal. The 503B pathway covers office-administered compounded preparations through FDA-registered outsourcing facilities. FDA registration verification is through the FDA Drug Establishment Registration database. Neither 503A nor 503B receives FDA pre-market approval for the compounded product. Pharmacy Compounding Accreditation Board (PCAB) accreditation provides additional quality assurance verification. USP Chapter 797 sterile compounding compliance addresses sterile preparation protocols. USP Chapter 800 hazardous drug handling compliance addresses worker and patient safety. Examples of compounded peptide preparations include compounded semaglutide and tirzepatide during FDA shortage list inclusion windows, compounded thymosin alpha-1 (not FDA-approved in US but approved as Zadaxin in approximately 35 countries outside the US), compounded BPC-157 and TB-500 for tissue repair contexts, and compounded sermorelin for growth hormone secretagogue contexts. AMA Code of Medical Ethics 1.1.5 framework requires documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding for compounded prescribing. AMA Code 2.1.1 establishes the broader informed consent framework.

Evidence Levels Range From Preclinical Animal Studies to FDA-Approved Indications

Peptide therapy evidence levels span four tiers from preclinical mechanistic studies to FDA-approved indications. The PSI framework distinguishes L1 preclinical, L2 animal studies, L3 human trials, and L4 FDA-approved.

PSI's evidence-level framework provides a transparent classification system for peptide therapy evidence quality. L1 (preclinical) covers in vitro studies, mechanistic biology, and computational modeling without animal or human data. L2 (animal studies) covers rodent, large-animal, and other animal model studies without human trial data. L3 (human trials) covers any human trial data including pilot studies, Phase 1 first-in-human safety studies, Phase 2 dose-finding studies, and Phase 3 pivotal trials. The L3 tier captures the full breadth of human evidence including trials that did not lead to FDA approval. L4 (FDA-approved) covers compounds with completed FDA pre-market review and approved indication-specific labels. The L4 tier is the strongest evidence anchoring. For visitor-facing communication, PSI uses the labels FDA Approved, Human Trials, Animal Studies, and Preclinical rather than the internal L1-L4 notation. The framework anchors the PSI compound library and bloodwork pages. For peptide drugs, L4 examples include the FDA-approved metabolic peptides (Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza), anabolic osteoporosis peptides (Forteo, Tymlos, Evenity), Tesamorelin for HIV-associated lipodystrophy, and Vyleesi for HSDD. For compounded peptides, the framework applies per indication and may span L1 to L3 with limited or no L4 anchoring in US contexts.

Indication Classes Span Six Primary Therapeutic Areas

Peptide therapy indication classes span six primary therapeutic areas including metabolic, immune, tissue repair, growth hormone, sexual health, and bone health. Each class has distinct FDA-approved and compounded peptide options.

Metabolic peptides include GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) for chronic weight management and type 2 diabetes. Anabolic osteoporosis peptides include PTH analogs (teriparatide, abaloparatide) and sclerostin antibodies (romosozumab) for high fracture risk osteoporosis. Growth hormone secretagogues include sermorelin (compounded GHRH analog), Tesamorelin (Egrifta FDA-approved for HIV-associated lipodystrophy), and somatropin (recombinant human growth hormone for diagnosed adult-onset growth hormone deficiency). Compounded tissue repair peptides include BPC-157 and TB-500 with evidence base primarily preclinical and limited human trial data. Sexual health peptides include bremelanotide (Vyleesi FDA-approved for HSDD in premenopausal women) and compounded PT-141 variants. Compounded immune peptides include thymosin alpha-1 (not FDA-approved in US, approved as Zadaxin in approximately 35 countries outside the US). Additional classes include compounded longevity research peptides (epitalon, MOTS-c, humanin), neuropeptides (selank, semax in compounded contexts), and many other emerging research peptides. The PSI compound library covers approximately 150 compounds spanning these classes. Visitor-facing classification uses FDA Approved, Human Trials, Animal Studies, or Preclinical labels per evidence tier.

Both FDA-Approved and Compounded Peptide Therapy Require Physician Prescription and Baseline Bloodwork

Both FDA-approved and compounded peptide therapy require a physician prescription, baseline bloodwork appropriate to the indication, and four-stage monitoring cadence across the therapy course. Self-sourcing from research chemical suppliers operates outside the validated clinical practice framework.

Physician prescription requirement applies across the peptide therapy landscape. FDA-approved peptides require a physician prescription per the FDA label and the Federal Food Drug and Cosmetic Act framework. Compounded peptides require a physician prescription per the FDA Compounding Quality Act of 2013 framework with AMA Code of Medical Ethics 1.1.5 governing off-label and compounded prescribing. Baseline bloodwork applies per the indication and peptide class. For GLP-1 receptor agonists, baseline includes hemoglobin A1c, eGFR via creatinine, lipase, and lipid panel. For anabolic osteoporosis peptides, baseline includes calcium, vitamin D, PTH, creatinine, and bone turnover markers CTX and P1NP. For growth hormone secretagogues, baseline includes IGF-1, glucose, A1c, and lipid panel plus dynamic testing for adult-onset GHD. For compounded peptide preparations, baseline includes CMP and CBC plus indication-specific markers per AMA Code 1.1.5 framework. The four-stage monitoring cadence applies across the class: baseline week 0, early follow-up week 4-8, stabilization month 3, and maintenance month 6 with annual continuation. Research-grade peptide self-sourcing from research chemical suppliers (typically labeled not for human use) operates outside the validated clinical practice framework and is not a legal substitute for physician-prescribed FDA-approved or compounded therapy. Adverse event reporting through FDA MedWatch applies for serious events on any FDA-approved or compounded peptide.

FDA-approved peptide drug class: pre-market review and Phase 3 evidence

The FDA pre-market review framework anchoring FDA-approved peptide therapy

FDA-approved peptide drugs have undergone FDA pre-market review under the New Drug Application (NDA) framework. The review includes preclinical safety pharmacology, Phase 1 first-in-human safety and pharmacokinetics, Phase 2 dose-finding and proof-of-concept, and Phase 3 pivotal efficacy and safety trials. Post-marketing commitments may include Phase 4 trials, registry studies, and ongoing safety surveillance.

The FDA-approved peptide drug class spans multiple therapeutic areas. For chronic weight management and type 2 diabetes, FDA-approved peptides include semaglutide (Wegovy NDA 215256 weight management, Ozempic NDA 209637 type 2 diabetes), tirzepatide (Zepbound NDA 217806 weight management, Mounjaro NDA 215866 type 2 diabetes), and liraglutide (Saxenda weight management, Victoza type 2 diabetes). Cardiovascular outcomes evidence includes SELECT 2023 (semaglutide in obesity without diabetes), SUSTAIN-6 (semaglutide in type 2 diabetes), and LEADER (liraglutide in type 2 diabetes).

For high fracture risk osteoporosis, FDA-approved peptides include teriparatide (Forteo NDA 021318), abaloparatide (Tymlos NDA 208743), and romosozumab (Evenity NDA 761062 with cardiovascular boxed warning). Evidence anchors include VERT (teriparatide), ACTIVE (abaloparatide), FRAME (romosozumab), and ARCH (romosozumab head-to-head vs alendronate). For growth hormone, Tesamorelin (Egrifta NDA 022505) is FDA-approved for HIV-associated lipodystrophy. Somatropin is FDA-approved for diagnosed adult-onset growth hormone deficiency. For sexual health, Vyleesi (bremelanotide NDA 210557) is FDA-approved for HSDD in premenopausal women per RECONNECT trials. The FDA-approved class provides the strongest evidence anchoring across the peptide therapy landscape.

Compounded peptide framework: 503A pharmacy and 503B outsourcing facility pathways

The FDA Compounding Quality Act of 2013 framework governing compounded peptide preparations

The FDA Compounding Quality Act of 2013 (Drug Quality and Security Act framework) established two compounding categories operating outside FDA pre-market approval. The 503A pathway covers individual prescription compounding through state pharmacy board licensed compounding pharmacies. State license verification is through the state pharmacy board portal for the state where the pharmacy operates. The 503B pathway covers office-administered compounded preparations through FDA-registered outsourcing facilities verified through the FDA Drug Establishment Registration database.

Quality assurance verification spans multiple frameworks. PCAB (Pharmacy Compounding Accreditation Board) accreditation provides additional quality assurance verification through the PCAB website. USP Chapter 797 sterile compounding compliance addresses aseptic technique, environmental monitoring, beyond-use dating, and personnel qualification. USP Chapter 800 hazardous drug handling compliance addresses worker safety and patient exposure protocols. Third-party purity and potency testing typically includes USP 71 sterility, USP 85 bacterial endotoxin, and HPLC potency analysis.

AMA Code of Medical Ethics 1.1.5 framework governs off-label and compounded prescribing. The framework requires documented risk-benefit assessment for the specific patient context, FDA-approved alternatives considered (per indication), monitoring requirements including baseline labs and follow-up cadence, and patient understanding through informed consent acknowledgment. AMA Code 2.1.1 establishes the broader informed consent framework. Compounded peptide examples include compounded semaglutide and tirzepatide during FDA shortage list inclusion windows, compounded thymosin alpha-1 (not FDA-approved in US, approved as Zadaxin internationally), compounded BPC-157 and TB-500 for tissue repair contexts, and compounded sermorelin for growth hormone secretagogue contexts. Salt-form variants of FDA-approved molecules (semaglutide sodium, semaglutide acetate) face FDA enforcement and do not qualify under shortage list compounding.

Evidence-level framework: preclinical to FDA-approved tiers

The four-tier evidence framework anchoring peptide therapy claims

For visitor-facing communication, PSI uses the labels FDA Approved, Human Trials, Animal Studies, and Preclinical rather than the internal L1-L4 notation. The framework anchors the PSI compound library, condition pages, comparison pages, and bloodwork pages. The transparency principle is that every claim is traceable to evidence tier. The framework supports physician archetype trust by making evidence quality explicit.

Examples spanning the framework include semaglutide at L4 (FDA-approved per Wegovy NDA 215256 and Ozempic NDA 209637 with SELECT 2023 NEJM cardiovascular outcomes evidence). Thymosin alpha-1 at L3 in international Zadaxin approval contexts but operates as L1-L2 for many off-label US compounded indications. BPC-157 at L1-L2 with primarily preclinical evidence base and limited human trial data. The framework allows honest communication about evidence quality without overstating or understating. The Editorial Standards page at peptidescienceinstitute.org/editorial-standards documents the framework methodology.

Specialty coordination across peptide therapy indication classes

Specialty practice coordination framework for indication-specific peptide therapy

Specialty practice coordination supports indication-specific peptide therapy across the therapeutic class. For metabolic peptides including GLP-1 receptor agonists, coordination with endocrinology, weight medicine, primary care, or internal medicine supports complex evaluation. For anabolic osteoporosis peptides, coordination with endocrinology, rheumatology, or primary care supports high fracture risk evaluation. For Evenity cardiovascular boxed warning compliance, coordination with cardiology supports the framework.

For growth hormone secretagogues, coordination with endocrinology supports diagnosed adult-onset growth hormone deficiency evaluation. Dynamic testing including insulin tolerance test, glucagon stimulation test, or macimorelin test applies per AACE 2019 GHD CPG framework. For compounded tissue repair peptides, coordination with sports medicine, orthopedics, or physiatry supports musculoskeletal indication context. For compounded immune peptides including thymosin alpha-1, coordination with immunology, infectious disease, or rheumatology supports indication-specific evaluation.

For sexual health peptides, coordination with women's health (for Vyleesi HSDD indication) or men's health supports indication-specific evaluation. For compounded sexual health peptides including PT-141 variants, AMA Code 1.1.5 framework applies. Across the class, the PSI physician directory provides verified physicians ordering comprehensive baseline bloodwork and verifying 503A or 503B pharmacy quality assurance for compounded contexts. State medical board license verification, ABMS board certification, and AMA Code 1.1.5 documentation practice are the verification gates for physician selection.

Research Suggests

Direction

Peptide therapy spans FDA-approved drugs and compounded preparations under distinct regulatory frameworks. The evidence base ranges from preclinical to FDA-approved tiers across six indication classes.

FDA-approved peptide drugs have undergone FDA pre-market review including Phase 3 trial evidence. Examples span metabolic peptides (semaglutide, tirzepatide, liraglutide), anabolic osteoporosis peptides (teriparatide, abaloparatide, romosozumab), growth hormone secretagogues (Tesamorelin Egrifta, somatropin), sexual health peptides (bremelanotide Vyleesi), and immune contexts (no FDA-approved peptide for primary immune indications in US though Zadaxin thymosin alpha-1 approved in approximately 35 countries outside US). Compounded peptide preparations operate under the FDA Compounding Quality Act of 2013 (503A pharmacy and 503B outsourcing facility framework). AMA Code of Medical Ethics 1.1.5 governs off-label and compounded prescribing. Evidence levels span L1 preclinical, L2 animal studies, L3 human trials, and L4 FDA-approved tiers.

Strongest evidence

FDA-approved peptide drugs have the strongest evidence anchoring including Phase 3 trial evidence and indication-specific labels.

FDA-approved peptide drugs anchored in Phase 3 trial evidence provide the strongest framework. For metabolic peptides, Wegovy and Ozempic semaglutide anchored in SELECT 2023 (Lincoff et al. NEJM cardiovascular outcomes in obesity without diabetes), SUSTAIN-6 (Marso et al. NEJM 2016 type 2 diabetes), and STEP trial program. Zepbound and Mounjaro tirzepatide anchored in SURMOUNT-1 (Jastreboff et al. NEJM 2022 weight management) and SURPASS trial program. Saxenda and Victoza liraglutide anchored in SCALE trials and LEADER (Marso et al. NEJM 2016 cardiovascular outcomes). For anabolic osteoporosis peptides, Forteo teriparatide anchored in VERT (Neer et al. NEJM 2001 fracture reduction). Tymlos abaloparatide anchored in ACTIVE (Miller et al. JAMA 2016 fracture reduction). Evenity romosozumab anchored in FRAME (Cosman et al. NEJM 2016) and ARCH (Saag et al. NEJM 2017) with FDA cardiovascular boxed warning April 2019. Tesamorelin Egrifta anchored in LIPO trials for HIV-associated lipodystrophy. Vyleesi bremelanotide anchored in RECONNECT trials for HSDD.

Limitations

Compounded peptide preparations operate outside FDA pre-market approval. Evidence base varies substantially across off-label and emerging compounded indications.

Compounded peptide preparations operate under the FDA Compounding Quality Act of 2013 without FDA pre-market approval for the compounded product. The 503A pathway requires state pharmacy board oversight. The 503B pathway requires FDA registration and inspection. AMA Code 1.1.5 framework requires documented consideration of FDA-approved alternatives before compounded prescribing. The evidence base for many off-label compounded indications is primarily preclinical with limited human trial data. Examples include compounded BPC-157 and TB-500 (tissue repair, primarily preclinical), compounded thymosin alpha-1 (not FDA-approved in US though approved internationally as Zadaxin for hepatitis B and C), compounded sermorelin (GHRH analog with primary regulatory consideration as not-FDA-approved for general use), and many emerging research peptides (epitalon, MOTS-c, humanin, semax, selank with primarily preclinical or limited human evidence base). Research-grade peptide self-sourcing operates outside the validated clinical practice framework entirely.

Assessment

The framework establishes peptide therapy foundations across FDA-approved drugs and compounded preparations. Physician prescription and baseline bloodwork are universal requirements.

PSI's reading: peptide therapy is well-anchored for FDA-approved indications across metabolic, osteoporosis, growth hormone, and sexual health classes through FDA pre-market review and Phase 3 trial evidence. The compounded peptide pathway operates under the FDA Compounding Quality Act of 2013 with state and federal oversight. AMA Code of Medical Ethics 1.1.5 framework provides the ethical anchoring for off-label and compounded prescribing. The evidence-level framework distinguishes preclinical, animal studies, human trials, and FDA-approved tiers with transparent visitor-facing labels. Physician prescription is required across the class. Baseline bloodwork applies per indication and peptide class per FDA labels or AMA Code 1.1.5 framework. The four-stage monitoring cadence (baseline week 0, early follow-up week 4-8, stabilization month 3, maintenance month 6 plus annual) applies across the class. Specialty coordination supports indication-specific evaluation. The PSI compound library covers approximately 150 compounds spanning the peptide therapy landscape. The PSI physician directory provides verified physicians with peptide therapy experience.

How to Approach Your Decision

Limitations and Caveats

FDA pre-market approval applies only to FDA-approved peptide drugs. Compounded preparations operate outside FDA pre-market approval per the FDA Compounding Quality Act of 2013.
Evidence base varies substantially across peptide therapy contexts. Some compounded indications have primarily preclinical evidence while FDA-approved peptides have Phase 3 trial anchoring.
AMA Code of Medical Ethics 1.1.5 documentation is required for off-label and compounded prescribing. The framework requires documented FDA-approved alternative consideration.
Salt-form variants of FDA-approved molecules face FDA enforcement. Semaglutide sodium and semaglutide acetate do not qualify under shortage list compounding.
Research-grade peptide self-sourcing operates outside validated clinical practice. Products labeled not for human use are not a legal substitute for physician-prescribed therapy.
Insurance coverage varies by FDA-approved indication match. Compounded peptide preparations are typically billed cash with insurance coverage limited or absent.
Long-term safety data is limited for many emerging compounded peptides. Conservative monitoring intervals strengthen the safety framework.
Specialty coordination strengthens complex evaluation. Endocrinology, weight medicine, rheumatology, sports medicine, immunology, and infectious disease provide indication-appropriate input.

What's Marketed vs What's Studied

7 common claims, corrected.

“All peptides are FDA-approved drugs.”

Only some peptides are FDA-approved drugs. Examples of FDA-approved peptides include Wegovy, Ozempic, Zepbound, Mounjaro, Forteo, Tymlos, Evenity, Tesamorelin Egrifta, and Vyleesi. Compounded peptide preparations operate under the FDA Compounding Quality Act of 2013 without FDA pre-market approval.

“Compounded peptides are the same as research-grade peptides sold online.”

Compounded peptides require a physician prescription and route through state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under the FDA Compounding Quality Act of 2013. Research-grade peptides labeled not for human use are sold for laboratory research and operate outside the validated clinical practice framework entirely.

“Peptide therapy does not require baseline bloodwork.”

Both FDA-approved and compounded peptide therapy require indication-specific baseline bloodwork. For GLP-1 receptor agonists, baseline includes A1c, eGFR, lipase, and lipid panel. For osteoporosis peptides, baseline includes calcium, vitamin D, PTH, creatinine, and bone turnover markers. For compounded peptides, baseline includes CMP and CBC plus indication-specific markers under AMA Code 1.1.5.

“Compounded semaglutide and tirzepatide are FDA-approved.”

Wegovy and Ozempic semaglutide are FDA-approved. Zepbound and Mounjaro tirzepatide are FDA-approved. Compounded semaglutide and compounded tirzepatide preparations are not FDA-approved. The compounded preparations operate under the FDA Compounding Quality Act framework with state pharmacy board or FDA outsourcing facility oversight.

“Thymosin alpha-1 is FDA-approved in the US.”

Thymosin alpha-1 is not FDA-approved in the US. The compound is approved as Zadaxin from SciClone Pharmaceuticals in approximately 35 countries outside the US for hepatitis B, hepatitis C, and other indications. In the US, thymosin alpha-1 is available only through compounded pathways under AMA Code 1.1.5 framework.

“BPC-157 has strong human clinical trial evidence.”

BPC-157 has primarily preclinical evidence base with limited human trial data. The compound is not FDA-approved in any country. Compounded BPC-157 prescribing in the US operates under AMA Code of Medical Ethics 1.1.5 with documented risk-benefit assessment and patient understanding of the evidence base limitations.

“Peptide therapy is interchangeable with anabolic steroid therapy.”

Peptides are short amino acid chains that function as biological signals. Anabolic steroids are modified testosterone derivatives that function through androgen receptor activation. The therapeutic categories are distinct mechanistically, regulatorily, and clinically. Some peptides like compounded growth hormone secretagogues face anti-doping organization scrutiny in athletic contexts.

Common Questions

What are peptides?

Peptides are short amino acid chains, typically fewer than 50 amino acids, that function as biological signals between cells. The class spans naturally occurring hormones (insulin, glucagon), neurotransmitters (oxytocin, vasopressin), immune modulators (thymosins, defensins), and synthetic therapeutic agents derived from endogenous templates. Therapeutic peptides include FDA-approved drugs and compounded preparations under different regulatory frameworks.

What is the difference between FDA-approved and compounded peptides?

FDA-approved peptides have undergone FDA pre-market review including Phase 3 trial evidence supporting safety and efficacy for the specific indication. Examples include Wegovy, Ozempic, Zepbound, Mounjaro, Forteo, Tymlos, and Evenity. Compounded peptide preparations route through 503A pharmacies or 503B outsourcing facilities under the FDA Compounding Quality Act of 2013 without FDA pre-market approval. AMA Code of Medical Ethics 1.1.5 governs off-label and compounded prescribing.

What FDA-approved peptide drugs are available for weight management?

FDA-approved peptide drugs for chronic weight management include Wegovy (semaglutide NDA 215256), Zepbound (tirzepatide NDA 217806), and Saxenda (liraglutide). For type 2 diabetes contexts, Ozempic (semaglutide NDA 209637), Mounjaro (tirzepatide NDA 215866), and Victoza (liraglutide) are FDA-approved. SELECT 2023 demonstrated cardiovascular benefit of semaglutide in obesity without diabetes.

What FDA-approved peptide drugs are available for osteoporosis?

FDA-approved peptide drugs for high fracture risk osteoporosis include Forteo (teriparatide NDA 021318), Tymlos (abaloparatide NDA 208743), and Evenity (romosozumab NDA 761062 with cardiovascular boxed warning). Forteo and Tymlos are PTH analogs anchored in VERT and ACTIVE trials. Evenity is a sclerostin antibody anchored in FRAME and ARCH trials.

Are compounded peptides legal?

Compounded peptide preparations are legal under the FDA Compounding Quality Act of 2013 framework. The 503A pathway covers individual prescription compounding through state pharmacy board licensed pharmacies. The 503B pathway covers office-administered preparations through FDA-registered outsourcing facilities. Both require a physician prescription. Neither receives FDA pre-market approval. AMA Code 1.1.5 framework governs prescribing.

What is AMA Code of Medical Ethics 1.1.5?

AMA Code of Medical Ethics Opinion 1.1.5 (Off-Label and Investigational Use of Pharmaceuticals) governs off-label and compounded prescribing. The framework requires documented risk-benefit assessment for the specific patient context, FDA-approved alternatives considered (per indication), monitoring requirements including baseline labs and follow-up cadence, and patient understanding through informed consent acknowledgment. AMA Code 2.1.1 establishes the broader informed consent framework.

What is the difference between 503A and 503B compounding?

The 503A pathway covers individual prescription compounding through state pharmacy board licensed compounding pharmacies. State license verification is through the state pharmacy board portal. The 503B pathway covers office-administered compounded preparations through FDA-registered outsourcing facilities. FDA registration verification is through the FDA Drug Establishment Registration database. Both require physician prescription. PCAB accreditation provides additional quality verification.

What is the PSI evidence-level framework?

PSI's evidence-level framework distinguishes four tiers. L1 preclinical covers in vitro and mechanistic studies. L2 animal studies covers rodent and other animal model studies without human trial data. L3 human trials covers any human trial data including pilot, Phase 1, Phase 2, and Phase 3. L4 FDA-approved covers compounds with completed FDA pre-market review. Visitor-facing labels are FDA Approved, Human Trials, Animal Studies, and Preclinical.

What baseline bloodwork is required before peptide therapy?

Baseline bloodwork depends on peptide class. For GLP-1 receptor agonists, baseline includes hemoglobin A1c, eGFR via creatinine, lipase, and lipid panel. For anabolic osteoporosis peptides, baseline includes calcium, vitamin D, PTH, creatinine, and bone turnover markers CTX and P1NP. For growth hormone secretagogues, baseline includes IGF-1, glucose, A1c, and lipid panel plus dynamic testing. For compounded peptides, baseline includes CMP and CBC plus indication-specific markers under AMA Code 1.1.5.

Do I need a physician prescription for peptide therapy?

Yes. Both FDA-approved and compounded peptide therapy require a physician prescription. FDA-approved peptides require prescription per the FDA label and Federal Food Drug and Cosmetic Act. Compounded peptides require prescription per the FDA Compounding Quality Act framework with AMA Code 1.1.5 governing off-label prescribing. Self-sourcing from research chemical suppliers operates outside the validated clinical practice framework.

Can I get peptide therapy through telehealth?

Yes. Telehealth peptide therapy is available across many indications. The framework includes telehealth consultation with a state-licensed physician, baseline bloodwork through external laboratory networks like Quest Diagnostics or LabCorp, prescription routing to retail pharmacy (FDA-approved) or compounding pharmacy (503A or 503B compounded), and follow-up monitoring via telehealth. State medical board telehealth practice rules apply.

What insurance coverage applies to peptide therapy?

Insurance coverage varies by FDA-approved indication match. FDA-approved peptides for type 2 diabetes (Ozempic, Mounjaro, Victoza) typically have insurance coverage with prior authorization. FDA-approved peptides for chronic weight management (Wegovy, Zepbound, Saxenda) have variable coverage. Compounded peptide preparations are typically billed cash with insurance coverage limited or absent. Baseline bloodwork has standard laboratory coverage.

What are common indication classes for peptide therapy?

Six primary indication classes apply. Metabolic peptides for chronic weight management and type 2 diabetes (GLP-1 receptor agonists). Anabolic osteoporosis peptides for high fracture risk (PTH analogs, sclerostin antibodies). Growth hormone secretagogues for diagnosed adult-onset GHD or HIV-associated lipodystrophy. Compounded tissue repair peptides for musculoskeletal contexts. Sexual health peptides for HSDD (Vyleesi). Compounded immune peptides for off-label immune contexts.

What is the four-stage monitoring cadence?

The four-stage monitoring cadence applies across peptide therapy. Stage 1 baseline at week 0 establishes the full panel and AMA Code 1.1.5 documentation for compounded contexts. Stage 2 early follow-up at week 4 to 8 tracks tolerability and side effect emergence. Stage 3 stabilization at month 3 captures steady-state response. Stage 4 maintenance at month 6 with annual continuation thereafter applies the full panel re-check.

What are SELECT, SUSTAIN, and SURMOUNT trials?

SELECT 2023 (Lincoff et al. NEJM) was a 17,604-patient cardiovascular outcomes trial demonstrating approximately 20 percent MACE reduction with semaglutide in obesity without diabetes. SUSTAIN-6 (Marso et al. NEJM 2016) demonstrated cardiovascular benefit of semaglutide in type 2 diabetes. SURMOUNT-1 (Jastreboff et al. NEJM 2022) was the pivotal weight management trial demonstrating approximately 21 percent weight reduction with tirzepatide.

What evidence is available for compounded BPC-157?

Compounded BPC-157 has primarily preclinical evidence base. The compound has been studied in rodent models for tendon healing, ligament repair, and gastrointestinal contexts. Human trial data is limited. The compound is not FDA-approved in any country. Compounded BPC-157 prescribing in the US operates under AMA Code 1.1.5 with documented patient understanding of evidence base limitations.

Where can I find a physician for peptide therapy?

The PSI physician directory provides verified physicians across major US cities including peptide therapy experience verification, state medical board license verification, ABMS board certification, and AMA Code 1.1.5 documentation practice verification. The directory covers primary care, endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, and men's health specialties.

How do I verify a compounding pharmacy for peptide therapy?

Pharmacy verification includes 503A state license verification through the state pharmacy board portal or 503B FDA registration verification through the FDA Drug Establishment Registration database. Additional verification includes PCAB accreditation status through the PCAB website, USP Chapter 797 sterile compounding compliance, USP Chapter 800 hazardous drug handling compliance, and third-party purity and potency testing documentation.

Sourcing Checklist

Obtain peptide therapy through physician prescription only.
Both FDA-approved and compounded peptides require a physician prescription. Self-sourcing from research chemical suppliers operates outside the validated clinical practice framework.
Confirm FDA approval status for the specific peptide drug and indication.
FDA approval status applies to the specific peptide and the specific indication. Off-label prescribing of FDA-approved peptides operates under AMA Code 1.1.5.
For compounded preparations, confirm AMA Code of Medical Ethics 1.1.5 documentation.
The documentation includes risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding.
Verify 503A state pharmacy license or 503B FDA registration for compounded preparations.
503A verification is through state pharmacy board portal. 503B verification is through FDA Drug Establishment Registration database.
Confirm PCAB accreditation status of the compounding pharmacy.
PCAB (Pharmacy Compounding Accreditation Board) accreditation is verified through the PCAB website and provides additional quality assurance verification.
Confirm USP Chapter 797 sterile compounding and USP Chapter 800 hazardous drug handling compliance.
USP 797 addresses aseptic technique, environmental monitoring, beyond-use dating. USP 800 addresses worker and patient safety protocols.
Request third-party purity and potency testing documentation for compounded preparations.
Testing typically includes USP 71 sterility, USP 85 bacterial endotoxin, and HPLC potency analysis for active ingredient verification.
Order indication-appropriate baseline bloodwork before peptide therapy initiation.
Baseline panel depends on peptide class per FDA labels for FDA-approved peptides or AMA Code 1.1.5 framework for compounded preparations.
Expect specialty coordination for indication-specific contexts.
Endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, and men's health support indication-appropriate evaluation.

Regulatory Context

The regulatory framework governing peptide therapy evolves continuously. FDA prescribing information for FDA-approved peptides updates periodically with new clinical data and post-marketing surveillance findings. FDA Compounding Quality Act enforcement evolves with state pharmacy board oversight cycles and 503B outsourcing facility inspection cadences. AMA Code of Medical Ethics 1.1.5 and 2.1.1 frameworks remain foundational. USP Chapter 797 and 800 standards update periodically. New FDA peptide approvals expand the FDA-approved class. International approvals like Zadaxin thymosin alpha-1 vary by country. PSI tracks regulatory changes and updates this page per the Editorial Standards review cadence.

Comparison

Pathway	Regulatory Framework	Pre-Market Review	Prescription Required
FDA-Approved Peptide Drug	FDA NDA/BLA pre-market review	Yes (Phase 3 trial evidence)	Yes (state medical board licensed physician)
503A Compounded Preparation	State pharmacy board licensed compounding pharmacy	No (compounded per individual prescription)	Yes (state medical board licensed physician)
503B Compounded Preparation	FDA-registered outsourcing facility	No (office-administered compounded)	Yes (state medical board licensed physician)
AMA Code 1.1.5 Framework	Mandatory for off-label and compounded prescribing	N/A (documentation only)	Documentation only, not a prescription
PCAB Accreditation	Pharmacy Compounding Accreditation Board	N/A (accreditation only)	N/A
USP Chapter 797	Sterile compounding standard	N/A (standard only)	N/A
USP Chapter 800	Hazardous drug handling standard	N/A (standard only)	N/A
Research Chemical Self-Sourcing	Outside FDA Compounding Quality Act framework	No	No (not a legal substitute for prescription)

Who This Applies To

· Adult new to peptide therapy seeking foundational orientation across the FDA-approved and compounded landscape.
· Adult considering chronic weight management peptide therapy with insurance prior authorization preparation.
· Adult considering type 2 diabetes peptide therapy under ADA 2024 Standards of Care framework.
· Postmenopausal woman with high fracture risk osteoporosis considering anabolic peptide therapy options.
· Adult considering compounded peptide therapy for off-label indication under AMA Code 1.1.5 framework.
· Patient evaluating FDA-approved versus compounded peptide pathway distinctions for indication match.
· Adult with diagnosed adult-onset growth hormone deficiency considering Tesamorelin or somatropin context.
· Adult considering bremelanotide (Vyleesi) for HSDD in premenopausal women per FDA label indication.
· Patient verifying 503A or 503B pharmacy quality assurance documentation for compounded preparation pathway.
· Patient considering telehealth peptide therapy consultation with external laboratory network baseline bloodwork.

Verdict

Peptide therapy spans FDA-approved drugs and compounded preparations under distinct regulatory frameworks. FDA-approved peptides like Wegovy, Ozempic, Zepbound, Mounjaro, Forteo, Tymlos, Evenity, Tesamorelin, and Vyleesi have undergone FDA pre-market review including Phase 3 trial evidence. Compounded peptide preparations route through 503A pharmacies or 503B outsourcing facilities under the FDA Compounding Quality Act of 2013. AMA Code of Medical Ethics 1.1.5 governs off-label and compounded prescribing. Evidence levels span L1 preclinical, L2 animal studies, L3 human trials, and L4 FDA-approved tiers. Six indication classes cover the therapeutic landscape: metabolic, immune, tissue repair, growth hormone, sexual health, and bone health. Universal requirements include physician prescription, indication-appropriate baseline bloodwork, and four-stage monitoring cadence. Patients should consult primary care or specialty practice for individualized clinical context.

In Plain Terms

Peptides are short chains of amino acids that work as signals in your body. Some peptides are FDA-approved drugs like Wegovy, Ozempic, or Forteo. These have gone through FDA review and have specific labels for specific conditions. Other peptides are compounded by special pharmacies. Compounded peptides need a doctor prescription too but have not gone through FDA pre-market approval. Examples include compounded BPC-157, TB-500, sermorelin, and thymosin alpha-1. The evidence base varies. Some peptides have strong human trial evidence. Others have mostly animal study evidence. Always get peptide therapy through a doctor. Research-grade peptides sold online for not for human use are not a legal substitute.

Peptides are small protein-like molecules that act as signals between cells. Some are FDA-approved drugs for weight loss, diabetes, or osteoporosis. Others are made by compounding pharmacies for specific patients. Both kinds need a doctor prescription. The FDA-approved ones have been studied more thoroughly. Compounded ones have less FDA oversight. The doctor decides which is right for your situation. Always get baseline bloodwork before starting. Follow-up bloodwork happens at weeks 4 to 8, month 3, month 6, and yearly thereafter.

Peptide therapy requires physician selection through state medical board license verification, ABMS board certification, AMA Code 1.1.5 documentation practice (for compounded contexts), and indication-appropriate specialty coordination. PSI maintains a vetted directory of practitioners with peptide therapy experience across primary care, endocrinology, weight medicine, rheumatology, sports medicine, immunology, infectious disease, women's health, and men's health.

Find a verified physician

PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.

Browse the directory Learn about the verification process →

Related Conditions

Related Education

Featured Compounds

Common Contexts

· Adult new to peptide therapy seeking foundational orientation
· Adult considering FDA-approved GLP-1 receptor agonist therapy for weight management or type 2 diabetes
· Postmenopausal woman with high fracture risk osteoporosis considering anabolic peptide therapy
· Adult with diagnosed adult-onset growth hormone deficiency considering Tesamorelin or somatropin
· Adult considering compounded peptide therapy for off-label tissue repair indication
· Adult considering compounded thymosin alpha-1 for off-label immune support context
· Adult considering bremelanotide Vyleesi for HSDD in premenopausal women per FDA label
· Patient evaluating FDA-approved versus compounded peptide pathway for indication match
· Patient verifying 503A or 503B pharmacy quality assurance for compounded preparation
· Patient considering telehealth peptide therapy consultation with external laboratory bloodwork

Important Context

This page is educational and does not constitute medical advice. The information presented reflects FDA prescribing information for FDA-approved peptide drugs (Wegovy NDA 215256, Ozempic NDA 209637, Zepbound NDA 217806, Mounjaro NDA 215866, Forteo NDA 021318, Tymlos NDA 208743, Evenity NDA 761062 with cardiovascular boxed warning, Tesamorelin Egrifta NDA 022505, Vyleesi NDA 210557), AMA Code of Medical Ethics 1.1.5 and 2.1.1 for off-label and compounded prescribing and informed consent, FDA Compounding Quality Act of 2013 framework (503A pharmacy and 503B outsourcing facility), USP General Chapter 797 sterile compounding standards, USP General Chapter 800 hazardous drug handling standards, ADA 2024 Standards of Care, AACE/ACE 2020 Postmenopausal Osteoporosis CPG, Endocrine Society 2019 Osteoporosis CPG, AACE 2019 Adult GHD CPG, and cardiovascular outcomes trial evidence including SELECT 2023, SUSTAIN-6, SURMOUNT-1, LEADER, VERT, ACTIVE, FRAME, and ARCH.

Your physician will determine the appropriate peptide therapy per your specific indication, your clinical context including underlying conditions and concurrent medications, your insurance coverage, and your prior peptide therapy history. The framework described here is general and does not substitute for individualized clinical judgment. Specialty coordination supports complex decisions across primary care, endocrinology, rheumatology, sports medicine, immunology, infectious disease, women's health, men's health, and other relevant specialties.

Self-ordering of bloodwork through direct-to-consumer laboratory services is not a substitute for physician-ordered baseline assessment with documented clinical interpretation. Quality clinical practice orders bloodwork in the context of the indication-specific evaluation and reviews results with the patient. Self-sourcing of peptide preparations outside physician-prescribing pathways operates outside the validated clinical practice framework. Research-grade peptide products labeled not for human use are not a legal substitute for physician-prescribed FDA-approved or compounded therapy.

Educational content only. Dosing should be determined by a qualified physician who can evaluate your individual situation. PSI does not provide personalized dosing guidance. Discuss with your physician before initiating any peptide therapy. For compounded preparations, AMA Code 1.1.5 framework applies including documented risk-benefit assessment, FDA-approved alternatives considered, monitoring requirements, and patient understanding.

Sources and Citations

[1] FDA Prescribing Information: Wegovy (semaglutide) injection 2.4 mg · 2024 · FDA NDA 215256 · Source
[2] FDA Prescribing Information: Ozempic (semaglutide) injection · 2024 · FDA NDA 209637 · Source
[3] FDA Prescribing Information: Zepbound (tirzepatide) injection · 2024 · FDA NDA 217806 · Source
[4] FDA Prescribing Information: Mounjaro (tirzepatide) injection · 2024 · FDA NDA 215866 · Source
[5] FDA Prescribing Information: Forteo (teriparatide) injection · 2020 · FDA NDA 021318 · Source
[6] FDA Prescribing Information: Tymlos (abaloparatide) injection · 2022 · FDA NDA 208743 · Source
[7] FDA Prescribing Information: Evenity (romosozumab-aqqg) injection with cardiovascular boxed warning · 2019 · FDA NDA 761062 · Source
[8] FDA Prescribing Information: Egrifta (tesamorelin) for HIV-associated lipodystrophy · 2023 · FDA NDA 022505 · Source
[9] FDA Prescribing Information: Vyleesi (bremelanotide) injection for HSDD in premenopausal women · 2023 · FDA NDA 210557 · Source
[10] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial) · New England Journal of Medicine · 2023 · DOI
[11] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · New England Journal of Medicine · 2022 · DOI
[12] Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) · New England Journal of Medicine · 2016 · DOI
[13] Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER trial) · New England Journal of Medicine · 2016 · DOI
[14] Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis (VERT trial) · New England Journal of Medicine · 2001 · DOI
[15] Miller PD, Hattersley G, Riis BJ, et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women with Osteoporosis (ACTIVE trial) · JAMA · 2016 · DOI
[16] Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis (FRAME trial) · New England Journal of Medicine · 2016 · DOI
[17] American Diabetes Association. Standards of Care in Diabetes 2024 · Diabetes Care · 2024 · DOI
[18] Camacho PM, Petak SM, Binkley N, et al. AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 Update · Endocrine Practice · 2020 · DOI
[19] AMA Code of Medical Ethics Opinion 1.1.5: Off-label and Investigational Use of Pharmaceuticals · American Medical Association · 2024 · Source
[20] AMA Code of Medical Ethics Opinion 2.1.1: Informed Consent · American Medical Association · 2024 · Source
[21] FDA Compounding Quality Act of 2013: 503A pharmacy and 503B outsourcing facility framework · US Food and Drug Administration · 2013 · Source
[22] USP General Chapter 797 Pharmaceutical Compounding - Sterile Preparations · United States Pharmacopeia · 2024 · Source
[23] FDA MedWatch: The FDA Safety Information and Adverse Event Reporting Program · US Food and Drug Administration · 2024 · Source

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.